Deruxtecan Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 160 MG Pharmaceutical Form: Injectable Lyophilized Powder; Crizotinib Concentration*: 250 MG; Enzalutamide Concentration: 40 MG; Ocrelizumab Concentration: 30 MG/ML Pharmaceutical Form: Solution for Infusion; Dapagliflozin Concentration: 10 MG; Evolocumab Concentration: 140 MG/ML Pharmaceutical Form: Injectable Solution Additional: With Applicator Pen; Ruxolitinib Concentration

Start: 2025-03-01
End: 2025-03-12
Location: MINISTERIO DA SAUDE - Secretaria Executiva - Subsecretaria de Assuntos Administrativos - Departamento de Logistica

MINISTERIO DA SAUDE - Secretaria Executiva - Subsecretaria de Assuntos Administrativos - Departamento de Logistica Brazil has Released a tender for Deruxtecan Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 160 MG Pharmaceutical Form: Injectable Lyophilized Powder; Crizotinib Concentration*: 250 MG; Enzalutamide Concentration: 40 MG; Ocrelizumab Concentration: 30 MG/ML Pharmaceutical Form: Solution for Infusion; Dapagliflozin Concentration: 10 MG; Evolocumab Concentration: 140 MG/ML Pharmaceutical Form: Injectable Solution Additional: With Applicator Pen; Ruxolitinib Concentration in Pharmaceuticals. The tender was released on Mar 01, 2025.

Country - Brazil

Summary - Deruxtecan Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 160 MG Pharmaceutical Form: Injectable Lyophilized Powder; Crizotinib Concentration*: 250 MG; Enzalutamide Concentration: 40 MG; Ocrelizumab Concentration: 30 MG/ML Pharmaceutical Form: Solution for Infusion; Dapagliflozin Concentration: 10 MG; Evolocumab Concentration: 140 MG/ML Pharmaceutical Form: Injectable Solution Additional: With Applicator Pen; Ruxolitinib Concentration

Deadline - Mar 12, 2025

MT reference number - 104183733

Product classification - Pharmaceutical products

Organization Details:

Address - Brazil

Contact details - 565656565

Tender notice no. - 76454545

MT Ref Id - 104183733

Document Type - Tender Notices

Notice Details and Documents:

Description - notice_title: Deruxtecan Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concentration: 100 MG Pharmaceutical Form: Injectable Lyophilized Powder; Trastuzumab Composition: Entansine Concent ration: 160 MG Pharmaceutical Form: Injectable Lyophilized Powder; Crizotinib Concentration*: 250 MG; Enzalutamide Concentration: 40 MG; Ocrelizumab Concentration: 30 MG/ML Pharmaceutical Form: Solution for Infusion; Dapagliflozin Concentration: 10 MG; Evolocumab Concentration: 140 MG/ML Pharmaceutical Form: Injectable Solution Additional: With Applicator Pen; Ruxolitinib Concentrationlocal title:: * Chamada Pública * convoca as empresas interes

Mt Ref Id - 104183733

Deadline - Mar 12, 2025

View more tenders for

Pharmaceutical products Tenders Brazil Tenders

Similar Tenders :

Most Searched